RE:NOVARTISMicrobix complaint relates specifically to Agriflu, which only accounts for a small fraction of that number you're posting for their whole vaccines division.
Here is a copy of the complaint and a relevant citation:
https://patentdocs.typepad.com/files/microbix-v-novartis.pdf
Upon information and belief, Novartis, directly or indirectly, has or will, ship, distribute, offer for sale, sell, import, advertise, and/or market its
infringing Agriflu product and/or other products throughout the United States, the State of Texas,
and the Eastern District of Texas. Upon information and belief, Novartis, has or will,
purposefully and voluntarily place its infringing Agriflu product and/or other products in a
distribution chain that foreseeably leads to it being sold in this judicial district as part of the
ordinary stream of commerce, and with the expectation that its product has been, and will be,
offered for sale to and purchased by consumers in this judicial district.
Agriflu seams to be a new, themerisol free vaccine that is new to the market and has, at east historically, been relatively limited in distribution relative to their Fluvirin and OptaFlu products: https://www.fiercevaccines.com/special-reports/top-10-selling-flu-vaccines-2012
Novartis had some issues with it a couple of years ago:
https://www.fiercevaccines.com/special-reports/agriflu
I don't know the current status of it, but this article seams to indicate it won't be shipped into the US this year:
https://www.bostonglobe.com/business/2014/07/03/novartis-begins-shipping-seasonal-flu-vaccines/hC5yl6UEHqa3Jr8wojWlnM/story.html
I think Europe is the bigger fish to fry here; but can't dig-up any specific market share figures (in doses or dollars).